CG Oncology, Inc. Common stock (CGON) stock analysis
In our weekly check, CG Oncology, Inc. Common stock is graded D (A to F). Of 21 checks on debt, profit, cash flow and trend: 9 pass, warnings: 2, red flags: 10.
About CG Oncology, Inc. Common stock
CG Oncology, Inc. Common stock is a Healthcare company (Biotechnology) based in the United States, listed on NASDAQ as CGON.
What our checks show for CGON
Red flags
- The net margin fell by 3727 points over 5 years, to -3851%: the company keeps less of each sale as profit.
- The gross margin fell by 202 points, to -102%: costs are rising faster than prices.
- Weak EPS forecast
- Weak EPS growth
- The company is losing money.
- Free cash flow is negative: the business spends more cash than it brings in.
- The price swings a lot: 54.4% annual volatility. Expect large ups and downs.
- The stock has fallen as much as 67% from a peak. Would you have held through that?
- Return on capital (ROCE) is zero or negative: the business does not earn on the money put into it.
- Free cash flow is negative, so no cash is left over to cover pay in shares.
Warning signs
- Operating cash flow is negative while the company reports a profit: the profit does not arrive as cash.
- The share count grew by 16% in 2 years: each shareholder owns a smaller slice.
Strengths
- Debt is low: 0.01x equity.
- Analysts expect revenue to grow about 530% a year over the next years.
- Analysts expect the net margin to improve by 3839 points from today's -3851%.
- Revenue grew 218% a year over the last 3 years.
- Beta 0.24: the stock usually moves less than the market.
Similar companies
BLTE · CAI · ARWR · IBRX · KOD · TXG
Questions
What grade does CG Oncology, Inc. Common stock (CGON) have?
In our weekly check, CG Oncology, Inc. Common stock is graded D (A to F). Of 21 checks on debt, profit, cash flow and trend: 9 pass, warnings: 2, red flags: 10. The grade is a risk check, not a buy or sell recommendation.
What are the main risks of CGON stock?
This week's biggest flags for CG Oncology, Inc. Common stock: Margins falling, Gross margin falling, Weak EPS forecast. In total 12 of 21 checks show a warning or a red flag.
What does CG Oncology, Inc. Common stock do?
CG Oncology, Inc. Common stock is a Healthcare company (Biotechnology) based in the United States, listed on NASDAQ as CGON.
The grade is a risk check, not a price forecast, and not investment advice. In our 10-year test (S&P 500, 2016-2026), stocks we graded A or B fell more than 30% 2-3 times less often than D or F, without a lower average return.
Updated 2026-11-14
Open the full analysis